Browsing by Author "Kantar, Asli"

Now showing 1 - 12 of 12

Association Between Heat Shock Protein-72 Gene Polymorphism and Chronic Renal Failure in Children
(2014) Gulleroglu, Kaan; Baskin, Esra; Kantar, Asli; Sahin, Feride; https://orcid.org/0000-0003-1434-3824; https://orcid.org/0000-0003-4361-8508; https://orcid.org/0000-0001-7308-9673; F-3294-2013; B-5785-2018; AAC-7232-2020
Eculizumab in the Treatment of Dense Deposit Disease
(2015) Gulleroglu, Kaan; Avci, Begum; Kantar, Asli; Ozdemir, Handan; Baskin, Esra; 0000-0002-5375-379X; 0000-0003-1434-3824; 0000-0002-7528-3557; 0000-0003-1434-3824; 0000-0003-4361-8508; GYU-5220-2022; AAJ-8833-2021; X-8540-2019; F-3294-2013; B-5785-2018
The Effect of Anti-hla Antibodies on Renal Graft Functions
(2014) Baskin, Esra; Gulleroglu, Kaan; Kantar, Asli; Kirnap, Mahir; Karakayali, Feza; Haberal, Aysegul; Moray, Gokhan; Haberal, Mehmet; https://orcid.org/0000-0003-4361-8508; https://orcid.org/0000-0003-1434-3824; https://orcid.org/0000-0002-1874-947X; https://orcid.org/0000-0003-2498-7287; https://orcid.org/0000-0002-3462-7632; B-5785-2018; F-3294-2013; AAH-9198-2019; AAB-3888-2021; AAE-1041-2021; AAJ-8097-2021
Effects of Hyperuricemia on Renal Function in Pediatric Renal Transplant Recipients
(2014) Baskın, Esra; Fidan, Cihan; Kantar, Asli; Gulleroglu, Kaan; https://orcid.org/0000-0003-4361-8508; https://orcid.org/0000-0002-9093-1524; https://orcid.org/0000-0003-1434-3824; B-5785-2018; F-5830-2019; AAJ-8833-2021
Effects of Late Acute Rejection on Graft Survival and Outcome in Pediatric Renal Transplant Recipients
(2015) Baskin, Esra; Kantar, Asli; Gulleroglu, Kaan; Ozmen, Esra; Ozdemir, Handan; Kirnap, Mahir; Moray, Gokhan; Haberal, Mehmet; 0000-0002-3462-7632; 0000-0002-7528-3557; 0000-0003-2498-7287; 0000-0003-1434-3824; 0000-0003-4361-8508; /0000-0003-1434-3824; AAJ-8097-2021; X-8540-2019; AAE-1041-2021; F-3294-2013; B-5785-2018; AAH-9198-2019; AAJ-8833-2021
Experience with Continuous Venovenous Hemodiafiltration in Four Newborns: A Case Series and Review of the Literature
(2015) Tugcu, Ali Ulas; Kantar, Asli; Abbasoglu, Aslihan; Ecevit, Ayse; Tarcan, Aylin; Baskin, Esra; 0000-0002-2232-8117; 0000-0003-4361-8508; 25330394; ABI-2113-2020; AAJ-4616-2021; B-5785-2018
When conventional methods for treating complicated problems such as acute and chronic renal failure or metabolic diseases fail, the therapy of choice is peritoneal dialysis (PD) in neonatal period. However, in cases that involve technical difficulties, such as bulky lesions in the abdomen or complications from previous abdominal surgeries, it is not always possible to place a peritoneal catheter. In such situations, continuous venovenous hemodiafiltration (CVVHDF) can be effective. This case series presents our experience in 2013 with the administration of CVVHDF to four patients in our neonatal intensive care unit who could not undergo PD for various reasons.
Fractalkine Receptor Gene Polymorphisms and Chronic Renal Disease
(2014) Gulleroglu, Kaan; Baskin, Esra; Kantar, Asli; Sahin, Feride; https://orcid.org/0000-0003-1434-3824; https://orcid.org/0000-0003-4361-8508; AAJ-8833-2021; B-5785-2018
Hepatic Diseases in Pediatric Renal Transplant Recipients
(2014) BaskIn, Esra; Ozçay, Figen; Kantar, Asli; Gusen, Murat; Kirnap, Mahir; Yildirim, Sedat; Moray, Gokhan; Haberal, Mehmet; https://orcid.org/0000-0003-4361-8508; https://orcid.org/0000-0002-5214-516X; https://orcid.org/0000-0002-5735-4315; https://orcid.org/0000-0003-2498-7287; https://orcid.org/0000-0002-3462-7632; B-5785-2018; ABG-5684-2020; AAH-9198-2019; AAF-4610-2019; AAE-1041-2021; AAJ-8097-2021
Long-Term Outcomes of Kidney Transplant Recipients With Juvenile Nephronophthisis
(2022) Avci, Begum; Baskin, Esra; Gulleroglu, Kaan; Yilmaz, Aysun Caltik; Kantar, Asli; Akdur, Aydincan; Moray, Gokhan; Haberal, Mehmet; 0000-0003-1434-3824; 0000-0003-0774-4419; 0000-0002-3462-7632; 35570616; AAJ-8833-2021; AAD-1877-2021; AAJ-8097-2021
Objectives: Nephronophthisis is the most common genetic cause of kidney failure in childhood. Treatment for nephronophthisis is symptomatic, and kidney transplant is a good treatment option when kidney failure has developed. We reported the outcomes of kidney transplant recipients with primary diagnosis of juvenile nephronophthisis who were followed-up in our center. Materials and Methods: We retrospectively examined medical records of 17 kidney transplant patients with a primary diagnosis of juvenile nephronophthisis. We compared this group of 17 patients with kidney transplant recipients who had other etiologies of kidney failure in terms of transplant age, donor type, immunosuppressive treatment, acute rejection, graft loss rates, and glomerular filtration rates at 1 and 5 years posttransplant (N = 180 total analyzed). Results: Among 180 kidney transplant recipients, the 17 patients (9.4%) with nephronophthisis had a mean age of 12.6 +/- 4.3 years and mean follow-up time posttransplant of 79.5 +/- 41.9 months. Five of 17 patients received a kidney transplant from a deceased donor (29.4%), and the remaining 12 patients (70.6%) received transplants from living related donors. Preemptive kidney transplant was performed in 4 patients (23.5%). There was a statistically significant difference (P < .05) in terms of acute rejection between patients with nephronophthisis (17.6%) versus patients with other primary diagnoses (34%). However, the patients with nephronophthisis versus those with other primary diagnoses were similar (P > .05) in terms of transplant age (12.6 +/- 4.3 vs 13.8 +/- 6.7 years, respectively) and follow-up time (79.5 +/- 41.9 vs 59.1 +/- 38.8 months, respectively). Donor type, immunosuppressive treatment, and 1-year (96.7 +/- 23.2 vs 97.6 +/- 28.4 mL/min/1.73 m(2)) and 5-year (84.7 +/- 31.1 vs 86.7 +/- 21.7 mL/min/1.73 m(2)) glomerular filtration rates were also similar (P > .05) between groups. Conclusions: Posttransplant prognosis was good among kidney transplant recipients with juvenile nephronophthisis.
Prophylactic Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome in A Pediatric Renal Transplant Patient
(2015) Avci, Begum; Baskin, Esra; Gulleroglu, Kaan; Kantar, Asli; Moray, Gokhan; Haberal, Mehmet; 0000-0002-3462-7632; 0000-0003-4361-8508; 0000-0003-1434-3824; 0000-0003-2498-7287; 0000-0003-1434-3824; 0000-0002-5375-379X; AAJ-8097-2021; B-5785-2018; F-3294-2013; AAE-1041-2021; AAJ-8833-2021; GYU-5220-2022
The Rate of BK Virus Infection in Pediatric Renal Transplant Patients
(2018) Baskin, Esra; Avci, Begum; Gulleroglu, Kaan; Kazanci, Ozlem; Kantar, Asli; Ecevit, Zafer; Ozdemir, Handan; Moray, Gokhan; Haberal, Mehmet; 0000-0003-4361-8508; 0000-0002-5375-379X; 0000-0003-1434-3824; 0000-0002-7528-3557; 0000-0003-2498-7287; 0000-0002-3462-7632; B-5785-2018; GYU-5220-2022; AAJ-8833-2021; X-8540-2019; AAE-1041-2021; AAJ-8097-2021
Success of Eculizumab in the Treatment of Atypical Hemolytic Uremic Syndrome
(2015) Baskin, Esra; Gulleroglu, Kaan; Kantar, Asli; Bayrakci, Umut; Ozkaya, Ozan; 0000-0003-1434-3824; 0000-0003-1434-3824; 0000-0003-4361-8508; 25384530; F-3294-2013; AAJ-8833-2021; B-5785-2018
Disorders of complement regulation are the most important etiology of atypical hemolytic uremic syndrome (aHUS). Recent studies demonstrate that eculizumab is beneficial in long-term aHUS treatment. We present a series of children with aHUS resistant to/dependent on plasma exchange (PE) who were treated with eculizumab. This was a retrospective study in which data were retrieved from the medical files of children who had received PE as treatment for aHUS. The data retrieved included age, sex, presenting symptoms, presence of diarrhea/vomiting, hospitalization duration, laboratory data on admission and follow-up, need for transfusion or dialysis, response to PE, response to eculizumab and outcome. Of the 15 children diagnosed with aHUS in 2011 and 2012 in our departments, ten were resistant to, or dependent on, plasma therapy and treated with eculizumab; these children were enrolled in the study. Three patients had relapses, and seven had a new diagnosis. Nine children had oliguria or anuria, and eight required dialysis. Hypertension was observed in six patients. Neurologic involvement developed in six patients, with the symptoms including seizures, loss of balance, vision loss and severe confusion. Five and five patients were resistant to and dependent on plasma therapy, respectively. Following the start of eculizumab treatment, all patients achieved full recovery of renal function and hematologic parameters. In our ten pediatric patients with aHUS who did not respond to PE, eculizumab was a lifesaving therapy and improved their quality of life. Early eculizumab use was a rescue therapy for renal function. Our results show that eculizumab is an effective treatment for aHUS. However, more studies are needed on the long-term efficacy and safety of eculizumab in children with aHUS and to determine the optimal duration of treatment.